GLOMERULOSCLEROSIS, FOCAL SEGMENTAL

Clinical trials for GLOMERULOSCLEROSIS, FOCAL SEGMENTAL explained in plain language.

Never miss a new study

Get alerted when new GLOMERULOSCLEROSIS, FOCAL SEGMENTAL trials appear

Sign up with your email to follow new studies for GLOMERULOSCLEROSIS, FOCAL SEGMENTAL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 2 Completed 1

Experimental drug targets genetic cause of kidney damage

Disease control Completed

This study tested an experimental drug called VX-147 in adults with a specific genetic form of kidney disease called APOL1-mediated FSGS. The trial involved 16 participants with confirmed genetic markers and kidney biopsy diagnosis. Researchers measured how well the drug reduced …

Matched conditions: GLOMERULOSCLEROSIS, FOCAL SEGMENTAL

Phase: PHASE2 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control

Last updated Mar 17, 2026 12:55 UTC

GLOMERULOSCLEROSIS, FOCAL SEGMENTAL

Get alerted when new GLOMERULOSCLEROSIS, FOCAL SEGMENTAL trials appear

Experimental drug targets genetic cause of kidney damage